These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1005 related articles for article (PubMed ID: 25727967)

  • 81. Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme.
    Valenzuela C; Torrisi SE; Kahn N; Quaresma M; Stowasser S; Kreuter M
    Respir Res; 2020 Jan; 21(1):7. PubMed ID: 31906942
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice.
    Okuda R; Hagiwara E; Baba T; Kitamura H; Kato T; Ogura T
    Respir Med; 2013 Sep; 107(9):1431-7. PubMed ID: 23849626
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Idiopathic pulmonary fibrosis: an update.
    Spagnolo P; Sverzellati N; Rossi G; Cavazza A; Tzouvelekis A; Crestani B; Vancheri C
    Ann Med; 2015 Feb; 47(1):15-27. PubMed ID: 25613170
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Nintedanib in the treatment of idiopathic pulmonary fibrosis.
    Mazzei ME; Richeldi L; Collard HR
    Ther Adv Respir Dis; 2015 Jun; 9(3):121-9. PubMed ID: 25862013
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study.
    Sgalla G; Lo Greco E; Calvello M; Varone F; Iovene B; Cerri S; Donatelli P; Vancheri A; Pavone M; Luppi F; Vancheri C; Richeldi L
    Respirology; 2020 Nov; 25(11):1144-1151. PubMed ID: 32190952
    [TBL] [Abstract][Full Text] [Related]  

  • 86. [Antifibrotic therapy and progressive lung fibrosis].
    Fellrath JM
    Rev Med Suisse; 2020 Jun; 16(698):1256-1260. PubMed ID: 32558455
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF).
    Aribindi K; Liu GY; Albertson TE
    Expert Rev Clin Pharmacol; 2024 Sep; 17(9):817-835. PubMed ID: 39192604
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update.
    Rodríguez-Portal JA
    Drugs R D; 2018 Mar; 18(1):19-25. PubMed ID: 29209910
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis.
    Ogura T; Taniguchi H; Azuma A; Inoue Y; Kondoh Y; Hasegawa Y; Bando M; Abe S; Mochizuki Y; Chida K; Klüglich M; Fujimoto T; Okazaki K; Tadayasu Y; Sakamoto W; Sugiyama Y
    Eur Respir J; 2015 May; 45(5):1382-92. PubMed ID: 25504994
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Management of Idiopathic Pulmonary Fibrosis.
    Pleasants R; Tighe RM
    Ann Pharmacother; 2019 Dec; 53(12):1238-1248. PubMed ID: 31280590
    [No Abstract]   [Full Text] [Related]  

  • 91. Pirfenidone: a novel agent for the treatment of idiopathic pulmonary fibrosis.
    Potts J; Yogaratnam D
    Ann Pharmacother; 2013 Mar; 47(3):361-7. PubMed ID: 23404802
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
    Xaubet A; Serrano-Mollar A; Ancochea J
    Expert Opin Pharmacother; 2014 Feb; 15(2):275-81. PubMed ID: 24308635
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Shedding light on developmental drugs for idiopathic pulmonary fibrosis.
    Spagnolo P; Bonella F; Ryerson CJ; Tzouvelekis A; Maher TM
    Expert Opin Investig Drugs; 2020 Aug; 29(8):797-808. PubMed ID: 32538186
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis: A retrospective study.
    Furuya K; Sakamoto S; Shimizu H; Sekiya M; Kinoshita A; Isshiki T; Sugino K; Matsumoto K; Homma S
    Respir Med; 2017 May; 126():93-99. PubMed ID: 28427556
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Guidelines for the medical treatment of idiopathic pulmonary fibrosis.
    Xaubet A; Molina-Molina M; Acosta O; Bollo E; Castillo D; Fernández-Fabrellas E; Rodríguez-Portal JA; Valenzuela C; Ancochea J
    Arch Bronconeumol; 2017 May; 53(5):263-269. PubMed ID: 28292522
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis.
    Khalil N; Manganas H; Ryerson CJ; Shapera S; Cantin AM; Hernandez P; Turcotte EE; Parker JM; Moran JE; Albert GR; Sawtell R; Hagerimana A; Laurin P; Gagnon L; Cesari F; Kolb M
    Eur Respir J; 2019 Mar; 53(3):. PubMed ID: 30578394
    [TBL] [Abstract][Full Text] [Related]  

  • 97. An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP).
    Costabel U; Albera C; Lancaster LH; Lin CY; Hormel P; Hulter HN; Noble PW
    Respiration; 2017; 94(5):408-415. PubMed ID: 28898890
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis.
    Sathiyamoorthy G; Sehgal S; Ashton RW
    South Med J; 2017 Jun; 110(6):393-398. PubMed ID: 28575896
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis.
    Ren H; Wang K; Yang H; Gao L
    Saudi Med J; 2017 Sep; 38(9):889-894. PubMed ID: 28889145
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions.
    Galli JA; Pandya A; Vega-Olivo M; Dass C; Zhao H; Criner GJ
    Respirology; 2017 Aug; 22(6):1171-1178. PubMed ID: 28317233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.